Clinical Trial Search

Primary: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24 — -0.13; -1.12; -1.12 Percentage of glycosylated hemoglobin — p=< 0.0001

Primary: PASI Percent Change From Baseline to Week 12 — 81.92; 81.91 Percent Change in PASI score

Primary: Early Mortality — 9; 13 Participants

Primary: All-cause Mortality up to Day 60 — 10; 10; 126; 126 Participants — p=0.949

Primary: Number of Participants With Undetectable SARS-CoV-2 at PCR at Day 7 After Randomization in the FAS — 7; 4; 0 Participants — p=0.0109

Primary: Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose — 19.8; 10.7 Percentage of participants — p=<0.0001

Primary: Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — 222 Participants

Primary: Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm…

Primary: Hypoglycemia Episode Rate — 5.29; 5.85; -3.05; -3.15 episodes per week — p=0.5028

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 — -21.2; -11.6 score on a scale — p=<0.0001

Primary: Invasive Disease Free Survival (iDFS) for Palbociclib vs. Placebo in Patients With High CPS-EG Score After Neoadjuvant Chemotherapy Receiving Standard Adjuvant Endocrine…

Primary: CIF of Major or Clinically Relevant Non-major Bleeding Combined With Death as Competing Risk — 9.6; 13.5 proportion of participants — p=0.3117

Primary: Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort — -1.718; -0.628 Score on a scale — p== 0.0063

Primary: Change in Leucocyte LC3 Score — 0.1; -1.8 Fold Change (Arbitrary Units)

Primary: Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version…